Bacteriophage Therapy for Multidrug-Resistant Biofilm Infections: Engineering Phage Cocktails, Host Range Expansion, and Clinical Translation Frameworks
Sr No:
Page No:
18-37
Language:
English
Authors:
Tiku Kevin Tebeck*, Tayo Nguetsa Marcellin Girez, Yene Zang Bernard Severin, Mbone Toukaba Ines Pascale, Badie Moupain Idriss
Affiliation:
University of Garoua, Faculty of medicine and Biomedical Science, Masters in Clinical Biology
Received:
2026-09-29
Accepted:
2026-11-03
Published Date:
2026-11-18
Abstract:
The accelerating crisis of antimicrobial resistance has rendered conventional
antibiotics ineffective against a growing spectrum of multidrug-resistant (MDR) pathogens,
particularly when these organisms establish biofilm communities on indwelling medical
devices, chronic wounds, and prosthetic implants. Biofilm-associated infections represent a
distinct therapeutic challenge: the three-dimensional extracellular polymeric substance (EPS)
matrix not only physically excludes most antimicrobials but also harbors metabolically dormant
persister cells that tolerate bactericidal concentrations of antibiotics. Bacteriophages, viruses
evolved specifically to parasitize bacterial hosts offer a mechanistically orthogonal therapeutic
modality that circumvents both chemical resistance mechanisms and biofilm architecture
through enzymatic depolymerase activity and self-amplifying lytic cascades.
This narrative review synthesizes current understanding across four intersecting domains that
have heretofore been examined in isolation: the molecular basis of biofilm recalcitrance to
antibiotics, phage-biofilm penetration dynamics, synthetic phage engineering strategies for host
range expansion and biofilm degradation, and emerging clinical translation frameworks
including compassionate-use programs and regulatory pathways. The synthesis reveals that
while individual phage strains demonstrate remarkable biofilm-degrading capacity in vitro,
clinical efficacy requires rationally designed phage cocktails that anticipate bacterial counterevolution, target multiple surface receptors, and encode complementary depolymerase enzymes.
Critical gaps emerge at the interface of phage biology and clinical implementation: standardized
manufacturing protocols remain absent, pharmacokinetic-pharmacodynamic relationships are
poorly characterized for biofilm contexts, and validated biomarkers of therapeutic response do
not exist. The regulatory landscape, while evolving through emergency investigational new
drug (IND) pathways, lacks harmonized frameworks for adaptive phage therapy where strain
selection must respond to real-time resistance emergence. Accumulating evidence from
compassionate-use cases at specialized centers demonstrates clinical resolution of otherwise
untreatable infections, yet the absence of randomized controlled trials limits broader adoption.
The path forward necessitates coordinated efforts across synthetic biology, clinical
microbiology, infectious disease medicine, and regulatory science. Immediate priorities include
establishing phage banks with pre-characterized host ranges, developing point-of-care phage
susceptibility testing, engineering broad-spectrum synthetic phages through tail fiber library
construction, and implementing adaptive trial designs that accommodate personalized phage
selection. The convergence of CRISPR-based antimicrobials, machine learning-guided phage
discovery, and three-dimensional biofilm models positions phage therapy not as a historical
curiosity but as a precision antimicrobial platform for the post-antibiotic era.
Keywords:
bacteriophage therapy, multidrug resistance, biofilm infections, phage engineering, synthetic biology, antimicrobial resistance, regulatory pathways, personalized antimicrobials.